| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 196.90 | -45 |
| Intrinsic value (DCF) | 140.79 | -61 |
| Graham-Dodd Method | 11.60 | -97 |
| Graham Formula | 104.50 | -71 |
Cencora, Inc. (formerly AmerisourceBergen Corporation) is a leading global pharmaceutical sourcing and distribution company headquartered in Conshohocken, Pennsylvania. Operating in the Medical Distribution industry under the Healthcare sector, Cencora provides a comprehensive range of services, including pharmaceutical distribution, pharmacy management, supply chain solutions, and clinical trial support. The company serves a diverse clientele, including hospitals, retail pharmacies, clinics, and biopharmaceutical manufacturers. Cencora's U.S. Healthcare Solutions segment focuses on domestic distribution, while its International Healthcare Solutions segment extends its reach to Europe and other global markets. With a market capitalization of approximately $56.8 billion, Cencora plays a pivotal role in the healthcare supply chain, ensuring the efficient delivery of pharmaceuticals and healthcare products. The company's rebranding to Cencora in 2023 reflects its strategic evolution and commitment to innovation in healthcare logistics and services.
Cencora presents a stable investment opportunity within the healthcare distribution sector, supported by its strong market position and consistent revenue streams. The company's diversified service offerings and global footprint mitigate risks associated with regional market fluctuations. With a beta of 0.6, Cencora exhibits lower volatility compared to the broader market, appealing to risk-averse investors. However, the thin net income margin (~0.5% of revenue) and significant total debt ($4.39 billion) warrant caution. The company's robust operating cash flow ($3.48 billion) and healthy dividend yield (~1.5% based on current market cap) add to its attractiveness. Investors should monitor regulatory pressures in pharmaceutical distribution and potential supply chain disruptions.
Cencora holds a competitive edge through its extensive distribution network and value-added services like pharmacy management and clinical trial support. Its scale allows for cost efficiencies and strong relationships with manufacturers and healthcare providers. The company's international segment provides geographic diversification, though it faces stiff competition in Europe from local players. Cencora's focus on specialty pharmaceuticals and biologics distribution differentiates it from generalist distributors. However, its lower net income margin compared to some peers suggests room for operational improvement. The company's rebranding signals a strategic shift towards integrated healthcare solutions, but execution risks remain. Its moderate beta indicates resilience to market downturns, a key advantage in the volatile healthcare sector. Cencora's ability to navigate regulatory complexities and maintain supplier relationships will be critical in sustaining its competitive position.